Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections

2 New Healthcare SPACs Worth Adding to Your Watch List

U.S. IPO Weekly Recap: The IPO Market Takes Its Annual February Break In A 1 IPO Week

FS Development Corp. II, Sponsored by Foresite Capital, Announces Pricing of Upsized $175 Million Initial Public Offering